================================================================================


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                   FORM 10-Q/A
                                 Amendment No. 1


                   [X] QUARTERLY REPORT PURSUANT TO SECTION 13
                     OR 15(d) OF THE SECURITIES EXCHANGE ACT
                                     OF 1934

                  For the quarterly period ended March 31, 2006

                                       OR

             [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                        For the transition period from to

                           Commission File No. 0-20260

                            IntegraMed America, Inc.
             (Exact name of Registrant as specified in its charter)


                Delaware                                06-1150326
     (State or other jurisdiction of       (I.R.S. employer identification no.)
      incorporation or organization)


        Two Manhattanville Road
           Purchase, New York                             10577
 (Address of principal executive offices)               (Zip code)

                          (914) 253-8000 (Registrant's
                     telephone number, including area code)

     Indicate by check mark if the registrant is a well-known  seasoned  issuer,
as defined in Rule 405 of the Securities Act. Yes _____ No __X__

     Indicate by check mark if the registrant is not required to file reports
pursuant to Section 13 or Section 15(d) of the Act.
Yes _____No __X__

     Indicate  by check mark  whether the  registrant  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days. Yes__X__ No ______


     Indicate by check mark if disclosure of delinquent filer pursuant to Item
405 of Regulation S-K (17 CFR 229.405) is not contained herein, and will not be
contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-K
or any amendment to this Form 10-K [ ].

     Indicate by check mark whether the registrant is a large accelerated filer,
an accelerated filer, or a non-accelerated filer. See definition of "accelerated
filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check
one): Large Accelerated Filer Accelerated Filer Non-Accelerated Filer X .

     Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act.
Yes ______ No __X__

         The aggregate number of shares of the Registrant's Common Stock, $.01
par value, outstanding on April 28, 2006 was 5,127,300.

================================================================================
<PAGE>




                            INTEGRAMED AMERICA, INC.
                                   FORM 10-Q/A

                                TABLE OF CONTENTS

                                                                           PAGE

PART I  -    FINANCIAL INFORMATION

    Explanatory Note......................................................... 3

    Item 1.  Financial Statements (unaudited)

              Consolidated Balance Sheets at March 31, 2006 and
                 December 31, 2005........................................... 4

              Consolidated Statements of Income for the three-month periods
                 ended March 31, 2006 and 2005 .............................. 5

              Consolidated Statements of Shareholders' Equity for
                 the three-month period ended March 31, 2006................. 6

              Consolidated Statements of Cash Flows for the three-month
                 periods ended March 31, 2006 and 2005 ...................... 7

              Notes to Consolidated Financial Statements ...................8-11

    Item 2.  Management's Discussion and Analysis of Financial Condition
                 and Results of Operations.................................12-17

    Item 3.  Quantitative and Qualitative Disclosures About Market Risk......18

    Item 4.  Controls and Procedures......................................... 18


PART II -    OTHER INFORMATION

    Item 1.  Legal Proceedings.............................................  19

    Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds...  19

    Item 3.  Defaults upon Senior Securities...............................  19

    Item 4.  Submission of Matters to a Vote of Security Holders...........  19

    Item 5.  Other Information.............................................  19

    Item 6.  Exhibits .....................................................  19


SIGNATURES   ..............................................................   20

CERTIFICATIONS PURSUANT TO 18 U.S.C. ss.1350, AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002...................................    EXHIBITS


CERTIFICATIONS PURSUANT TO 18 U.S.C ss.1350, AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002...................................    EXHIBITS



                                       2
<PAGE>


                                Explanatory Note

During October 2006, we provided notification that our financial statements for
2005 and the first two quarters of 2006 could not be relied upon, and will be
restated due to an accounting error. The restatements will not result in any
changes to net income or earnings per share for any period, but will, as of
March 31, 2006, have the effect of increasing Intangible assets by $1,934,000,
decreasing deferred tax assets by $784,000 and increasing deferred tax
liabilities by $1,150,000, all non-cash items.

Except as discussed above, and except as required to reflect the effects of the
restatement in this Form 10-Q/A, we have not modified or updated disclosures
presented in the original quarterly report on Form 10-Q. Accordingly, this Form
10-Q/A does not reflect events occurring after the filing of our original Form
10-Q or modify or update those disclosures affected by subsequent events, except
as specifically referenced herein. Information not affected by the restatement
is unchanged and reflects the disclosures made at the time of the original
filing of the Form 10-Q. Accordingly, this Form 10-Q/A should be read in
conjunction with our periodic filings made with the SEC subsequent to the date
of the original filing, including any amendments to those filings, as well as
any Current Reports filed on Form 8-K subsequent to the date of the original
filing. The following items have been amended as a result of the restatement:

         Part 1 - Item 1 - Financial Statements

         Part 1 - Item 2 - Management's Discussion and Analysis

         Part 1 - Item 4 - Controls and Procedures

In addition, in accordance with applicable SEC rules, this amended Quarterly
Report on Form 10-Q/A includes updated certifications from our Chief Executive
Officer (CEO) and Chief Financial Officer (CFO).

Please refer to Note 2 to the accompanying Consolidated Financial Statements for
additional information on the restatement.



                                       3
<PAGE>



PART I -- FINANCIAL INFORMATION

    Item 1.      Consolidated Financial Statements
<TABLE>

                            INTEGRAMED AMERICA, INC.
                           CONSOLIDATED BALANCE SHEETS
                (all dollars in thousands, except share amounts)
<CAPTION>
                                     ASSETS

                                                                                   March 31,   December 31,
                                                                                   ---------   ------------
                                                                                     2006         2005
                                                                                   ---------   ------------
                                                                                  (unaudited)
<S>                                                                                <C>         <C>
ASSETS
Current assets:
   Cash and cash equivalents ...................................................   $ 19,917    $ 22,521
   Pharmaceutical and other receivables, net ...................................        875         490
   Deferred income taxes, net ..................................................        895         999
   Prepaids and other current assets ...........................................      4,289       2,768
                                                                                   --------    --------
       Total current assets ....................................................     25,976      26,778

   Fixed assets, net ...........................................................     14,513      14,877
   Exclusive Service Rights and other intangibles, net .........................     24,014      24,388
   Other assets ................................................................        651         590
                                                                                   --------    --------
       Total assets ............................................................   $ 65,154    $ 66,633
                                                                                   ========    ========

                                        LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
   Accounts payable ............................................................   $    623    $    917
   Accrued liabilities .........................................................      6,989       8,023
   Current portion of long-term notes payable and other obligations ............      1,501       1,500
   Due to medical practices ....................................................      3,984       4,949
   Shared Risk Refund program patient deposits .................................      5,009       4,739
                                                                                   --------    --------
       Total current liabilities ...............................................     18,106      20,128

Deferred tax liability .........................................................      1,150       1,058
Long-term notes payable and other obligations ..................................      8,271       8,647
                                                                                   --------    --------

Total Liabilities ..............................................................     27,527      29,833

Commitments and Contingencies

Shareholders' equity:
   Common Stock, $.01 par value - 15,000,000 shares authorized; 5,127,300 and
      5,102,627 shares issued and
     outstanding in 2006 and 2005, respectively ................................         51          51
   Capital in excess of par ....................................................     49,465      49,747
   Deferred Compensation .......................................................       (658)       (354)
   Treasury stock, at cost - 0 and 105,768 shares in 2006 and 2005, respectively       --          (937)
   Accumulated deficit .........................................................    (11,231)    (11,707)
                                                                                   --------    --------
       Total shareholders' equity ..............................................     37,627      36,800
                                                                                   --------    --------

       Total liabilities and shareholders' equity ..............................   $ 65,154    $ 66,633
                                                                                   ========    ========

</TABLE>


        See accompanying notes to the consolidated financial statements.



                                       4
<PAGE>



                            INTEGRAMED AMERICA, INC.
                        CONSOLIDATED STATEMENTS OF INCOME
              (all amounts in thousands, except per share amounts)


                                                    For the
                                              three-month period
                                                ended March 31,
                                              ------------------
                                              2006         2005
                                              ----         ----
                                                 (unaudited)

Revenues, net
   Provider Services ....................   $ 27,776    $ 25,714
   Consumer Services ....................      2,658       6,249
                                            --------    --------
       Total revenues ...................     30,434      31,963

Costs of revenues:
   Provider Services costs ..............     25,032      23,019
   Consumer Services costs ..............      1,640       5,611
                                            --------    --------
       Total costs of revenues ..........     26,672      28,630
                                            --------    --------

Contribution
   Provider Services contribution .......      2,744       2,695
   Consumer Services contribution .......      1,018         638
                                            --------    --------
       Total contribution ...............      3,762       3,333

General and administrative expenses .....      3,052       2,834
Interest income .........................       (221)       (100)
Interest expense ........................        159          97
                                            --------    --------
       Total other expenses .............      2,990       2,831
                                            --------    --------

Income before income taxes ..............        772         502
Income tax provision ....................        296         188
                                            --------    --------

Net income ..............................   $    476    $    314
                                            ========    ========

Basic and diluted net earnings per share:
   Basic earnings per share .............   $   0.09    $   0.07
                                            ========    ========
   Diluted earnings per share ...........   $   0.09    $   0.06
                                            ========    ========

   Weighted average shares - basic ......      5,201       4,740
                                            ========    ========
   Weighted average shares - diluted ....      5,303       5,010
                                            ========    ========


        See accompanying notes to the consolidated financial statements.



                                       5
<PAGE>

<TABLE>


                            INTEGRAMED AMERICA, INC.
                 CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
                           (all amounts in thousands)
                                   (unaudited)

<CAPTION>

                                      Common Stock     Capital in      Deferred    Treasury Stock    Accumulated Total
                                     Shares   Amount  Excess of Par  Compensation  Shares   Amount     Deficit  Equity
                                     ------   ------  -------------  ------------  ------   ------     -------  ------


<S>                                     <C>    <C>       <C>            <C>          <C>    <C>       <C>       <C>
BALANCE AT DECEMBER 31, 2005            5,103  $ 51      $49,747        $(354)       106    $(937)    $(11,707) $36,800

Restricted Stock Grant                     32    --          400         (400)        --       --           --       --
Stock grant amortization                   --    --           --           96         --       --           --       96
Options and warrants exercised            108     1          315           --         10     (121)          --      195
Stock Option expense                       --    --           60           --         --       --           --       60
Cancellation of Treasury Stock           (116)   (1)      (1,057)          --       (116)   1,058           --       --
Net income for the quarter ended 03/31/06  --    --           --           --         --       --          476      476
                                         -----  ----     -------        -----       ----    -----     --------  -------

BALANCE AT MARCH 31, 2006               5,127  $ 51      $49,465        $(658)        --    $  --     $(11,231) $37,627
                                        =====  ====      =======        =====       ====    =====     ========  =======

</TABLE>



        See accompanying notes to the consolidated financial statements.



                                       6
<PAGE>

<TABLE>


                            INTEGRAMED AMERICA, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                           (all amounts in thousands)
<CAPTION>


                                                                            For the
                                                                      three-month period
                                                                        ended March 31,
                                                                      --------------------
                                                                         2006        2005
                                                                      ---------    -------

<S>                                                                    <C>         <C>
Cash flows from operating activities:
    Net income .....................................................   $    476    $    314
    Adjustments to reconcile net income to
    Net cash provided by (used in) operating activities:
      Depreciation and amortization ................................      1,421       1,318
      Deferred income tax provision ................................        216         127
      Stock-based compensation .....................................         96          60
    Changes in assets and liabilities Decrease (increase) in assets:
         Pharmaceutical and other accounts receivable ..............       (385)       (205)
         Prepaids and other current assets .........................     (1,521)     (1,807)
         Other assets ..............................................        (61)       (117)
      Increase (decrease) in liabilities:
         Accounts payable ..........................................       (294)        263
         Accrued liabilities .......................................       (994)       (191)
         Due to medical practices ..................................       (965)     (1,255)
         Shared Risk Refund program patient deposits ...............        270       1,045
                                                                       --------    --------
Net cash provided by (used in) operating activities ................     (1,741)       (448)

Cash flows from investing activities:
    Payment for exclusive FertilityPartners service rights .........       --        (3,325)
    Purchase of fixed assets and leasehold improvements ............       (683)     (2,078)
                                                                       --------    --------
Net cash provided by (used in) investing activities ................       (683)     (5,403)

Cash flows from financing activities:
    Principal repayments on debt ...................................       (357)       (287)
    Principal repayments under capital lease obligations ...........        (18)        (16)
    Exercise of common stock options and warrants ..................        195         187
                                                                       --------    --------
Net cash provided by (used in) financing activities ................       (180)       (116)

Net increase (decrease) in cash and cash equivalents ...............     (2,604)     (5,967)
Cash and cash equivalents at beginning of period ...................     22,521      11,300
                                                                       --------    --------
Cash and cash equivalents at end of period .........................   $ 19,917    $  5,333
                                                                       ========    ========

Supplemental Information:
     Interest paid .................................................   $    282    $    228
     Income taxes paid .............................................   $    969    $     75

</TABLE>


        See accompanying notes to the consolidated financial statements.



                                       7
<PAGE>



                            INTEGRAMED AMERICA, INC.
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)

NOTE 1 -- INTERIM RESULTS:

     The accompanying unaudited consolidated financial statements have been
prepared in accordance with the instructions to Form 10-Q and, accordingly, do
not include all of the information and footnotes required by generally accepted
accounting principles for complete financial statements. In the opinion of
management, the accompanying unaudited interim financial statements contain all
adjustments (consisting only of normal recurring accruals) necessary to present
fairly the financial position at March 31, 2006, and the results of operations
and cash flows for the interim periods presented. Operating results for the
interim period are not necessarily indicative of results that may be expected
for the year ending December 31, 2006. These financial statements should be read
in conjunction with the audited financial statements and notes thereto included
in IntegraMed America's Annual Report on Form 10-K for the year ended December
31, 2005.

Certain amounts from our March 31, 2005 presentations have been reclassified to
conform with our current 2006 presentation.

NOTE 2 -- RESTATEMENT:

     During October 2006, we provided notification that our financial statements
for 2005 and the first two quarters of 2006 could not be relied on, and would be
restated due to an accounting error. The restatements will not result in any
changes to net income or earnings per share for any period.

     The restatement was required in order to correct an error regarding the
deferred income tax accounting of acquiring the stock of Reproductive Partners,
Inc. in January 2005 in accordance with Financial Accounting Standards Board
Emerging Issues Taskforce Issue No. 98-11 "Accounting for Acquired Temporary
Differences in Certain Purchase Transactions That Are Not Accounted for as
Business Combinations". The following table illustrates the impact of the
correction:
<TABLE>
<CAPTION>

                                                 Three Months Ended                 Three Months Ended
                                                   March 31, 2006                     March 31, 2005
                                            -------------------------           ------------------------
                                            As Previously                      As Previously
                                               Reported     Restated              Reported       Restated
                                               --------     --------              --------       --------
<S>                                              <C>           <C>                <C>          <C>
Statement of Operations Summary:
     Revenues...............................     30,454        30,434             31,983       31,963
     Income before taxes....................        792           772                522          502
     Income tax provision...................        316           296                208          188
     Net income.............................        476           476                314          314
     Earnings Per Share.....................       0.07         0.07                0.06         0.06

Balance Sheet Summary:
March 31, 2006
     Total Assets...........................     64,004        65,154             53,942       54,585
     Total Liabilities......................     26,377        27,527             18,938       19,581
     Total Stockholders Equity..............     37,627        37,627             35,004       35,004
</TABLE>

The information related to December 31, 2005 and March 31, 2005 contained in
this document has been restated to reflect the correction of the error described
above.




                                       8
<PAGE>

                            INTEGRAMED AMERICA, INC.
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
                                   (unaudited)


NOTE 3 -- COMMON SHARES OUTSTANDING:

   All common share numbers reported herein reflect the 30% Stock Split effected
in the form of a Dividend declared by the Board of Directors on May 23, 2005 and
paid to shareholders on June 22, 2005.

NOTE 4 -- EARNINGS PER SHARE:

     The reconciliation of the numerators and denominators of the basic and
diluted EPS computations for the three-month periods ended March 31, 2006 and
2005 is as follows (000's omitted, except for per share amounts):

                                                             For the
                                                       three-month period
                                                         ended March 31,
                                                       -------------------
                                                        2006         2005
                                                       ------       ------

Numerator
Net Income.........................................    $   476      $   314
                                                       =======      =======

Denominator
Weighted average shares outstanding (basic)........      5,201        4,740
Effect of dilutive options and warrants............        102          270
                                                       -------      -------
Weighted average shares and dilutive potential
     Common shares (diluted).......................      5,303        5,010
                                                        ======       ======
Basic EPS..........................................   $   0.09     $   0.07
                                                      ========     ========
Diluted EPS........................................   $   0.09     $   0.06
                                                      ========     ========

     For the three-month periods ended March 31, 2006 and 2005, there were no
outstanding options or warrants to purchase shares of Common Stock which were
excluded from the computation of the diluted earnings per share amount as the
exercise prices of all outstanding options and warrants was less than the
average market price of the shares of Common Stock.

NOTE 5 -- SEGMENT INFORMATION:

     We follow the requirements contained in Statement of Financial Accounting
Standards (SFAS) No.131, "Disclosures about Segments of an Enterprise and
Related Information," with respect to identifying and reporting business
segments. This statement requires that segment reporting reflect our
organizational structure, major revenue sources, lines of responsibility and
senior management's perspective of an organization. In order to better execute
our business strategy and prepare for opportunities offered in the healthcare
marketplace, we modified our reporting segments in 2005. We currently report two
major lines of business, our Provider Services, which is comprised of our
FertilityPartners and Affiliate segments, and our Consumer Services, which is
comprised of our Shared Risk and Pharmaceutical segments.



                                       9
<PAGE>

                            INTEGRAMED AMERICA, INC.
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
                                   (unaudited)

<TABLE>
<CAPTION>

                                                                 Providers                 Consumers
                                                          Fertility                  Shared
                                               Corporate  Partners    Affiliates      Risk    Pharmaceutical     Consolidated
                                               ---------  --------    ----------      ----    --------------     ------------
<S>                                            <C>          <C>          <C>         <C>          <C>              <C>
For the three months ended March 31, 2006
     Revenues.............................     $    --      $27,497      $ 279       $2,505       $   153          $30,434
     Cost of Services.....................         ---       25,031          1        1,640            --           26,672
                                               -------      -------     ------       ------       --------         -------
     Contribution.........................         ---        2,466        278          865           153            3,762
     Operating Margin.....................          --          9.0%      99.6%        34.5%        100.0%             12.4%

     General and administrative...........       3,052           --         --           --            --            3,052
     Interest, net........................         (62)          --         --           --            --              (62)
                                               -------      -------     ------       ------       --------         -------
     Income before income taxes...........      (2,990)       2,466        278          865           153              772
     Depreciation expense included above..     $   139      $   908      $  --       $   --       $    --          $ 1,047
     Capital expenditures.................     $   174      $   509      $  --       $   --       $    --          $    683
     Total assets.........................     $22,783      $41,219      $  90       $  523       $   539          $65,154

For the three months ended March 31, 2005
     Revenues.............................     $    --      $25,467       $247       $1,510       $ 4,739          $31,963
     Cost of Services.....................         ---       22,967         52        1,060         4,551           28,630
                                               -------      -------     ------       ------       --------         -------
     Contribution.........................         ---        2,500        195          450           188            3,333
     Operating Margin.....................          --          9.9%      78.9%        29.8%          4.0%            10.5%

     General and administrative...........       2,834           --         --           --            --            2,834
     Interest, net........................          (3)          --         --           --            --               (3)
                                               -------      -------     ------       ------       --------         -------
     Income before income taxes...........      (2,831)       2,500        195          450           188              502
     Depreciation expense included above..     $    92      $   853      $  --       $   --      $     --          $   945
     Capital expenditures.................     $   264      $ 1,814      $  --       $   --      $     --          $ 2,078
     Total assets.........................     $ 7,537      $44,874      $  82       $  486      $  1,606          $54,585

As of December 31, 2005
     Total assets.........................     $22,992      $41,207      $  46       $  241      $  2,147          $66,633
</TABLE>

NOTE 6 - DUE TO MEDICAL PRACTICES

     Due to Medical Practices is comprised of the net amounts owed by us to
medical practices contracted as FertilityPartners. This balance is comprised of
amounts due to us by the medical practices for funds, which we advanced for use
in financing their accounts receivable, less balances owed to the medical
practices by us for undistributed physician earnings and patient deposits we
hold on behalf of the medical practices.

     As of March 31, 2006 and December 31, 2005, Due to Medical Practices was
comprised of the following balances:

                                                      2005            2004
                                                    ---------      ---------

       Advances to FertilityPartners..............   $(13,529)      $(12,727)
       Undistributed Physician Earnings...........      2,534          3,721
       Physician practice patient Deposits........     14,979         13,955
                                                    ---------      ---------
       Due to Medical Practices, net..............  $   3,984      $   4,949
                                                    =========      =========

                                       10
<PAGE>
                            INTEGRAMED AMERICA, INC.
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
                                   (unaudited)

NOTE 7 -- STOCK-BASED EMPLOYEE COMPENSATION:

     As of March 31, 2006, we had two stock-based employee compensation plans,
which are described more fully in Note 13 of the financial statements in our
most recent Annual Report on Form 10-K.

      In December 2004, the FASB issued SFAS No. 123 (revised 2004), "Share
Based Payment" ("SFAS No. 123(R)"). SFAS No. 123(R) supersedes APB Opinion No.
25, "Accounting for Stock Issued to Employees". In 2005, we used APB Opinion No.
25 to account for the value of stock options granted to employees. Effective
January 1, 2006, we adopted SFAS No. 123(R). In the first quarter of 2006, the
adoption of SFAS No. 123(R) resulted in a charge to earnings of $60,000 for the
value of outstanding stock options issued in prior years. As of March, 31, 2006,
we also had approximately $27,000 of unrecognized compensation cost related to
non-vested stock options which had been previously granted under our plans. That
cost is expected to be recognized during the second quarter of 2006. This
expected cost does not include the impact of any future stock-based compensation
awards.

     We also issue restricted stock grants to several officers and members of
the Board of Directors. Stock granted to Board members vests immediately and
stock granted to officers vests over a period of three years. Our General and
Administrative expense includes compensation costs recognized in connection with
these restricted stock grants of $96,000 and $84,000 for the three month periods
ended March 31, 2006 and March 31, 2005 respectively.


NOTE 8 -- LITIGATION

     From time to time, we are party to legal proceedings in the ordinary course
of business. As of March 31, 2006, none of these proceedings is expected to have
a material adverse effect on our financial position, results of operations or
cash flow.

NOTE 9 -- RECENT ACCOUNTING STANDARDS

     We disclose our critical accounting policies in our Form 10-K filed with
the Securities and Exchange Commission. Since our most recent Form 10-K filing
on December 31, 2005, none of those policies has changed, nor has any been
added. At this time, there are no recently issued accounting standards which are
expected to have a material impact on us.





                                       11
<PAGE>

Item 2.  Management's Discussion and Analysis of Financial Condition and
           Results of Operations


     The following discussion and analysis should be read in conjunction with
the consolidated financial statements and notes thereto included in this
quarterly report and with IntegraMed America Inc.'s Annual Report on Form 10-K
for the year ended December 31, 2005.

Overview

     IntegraMed America, Inc. offers products and services to patients and
providers in the fertility industry. We have developed a network comprised of
twenty-seven contracted fertility centers in major markets across the United
States, products and services designed to support fertility center growth,
products in the pharmaceutical and patient financing areas, and captive
insurance offerings. Nineteen affiliate fertility centers purchase discrete
service packages provided by us and have the right to distribute our consumer
products, and eight fertility centers have access to our entire portfolio of
products and services under our comprehensive FertilityPartners(TM) program. All
twenty-seven centers have access to our consumer services, principally
pharmaceutical products, and patient financing products.

     The business strategy of our Provider Services segment is to leverage our
deep expertise and commitment to improved fertility center performance by
providing the best value-specific offerings and an overall long term
relationship. The business strategy of our Consumer Segment is to provide
products and services that make obtaining high quality care easier and more
affordable. The primary elements of our strategy include: (i) expanding our
network of fertility centers to the top 50 markets in the United States; (ii) ;
(iii) increasing revenues and profits at contracted fertility centers;; and,
(iv) increasing sales of pharmaceutical and treatment financing products to
fertility patients.

Major events impacting financial condition and results of operations

     In December 2005, we amended our existing credit agreement with Bank of
America. The amended agreement is comprised of a renewal and increase in our
three-year revolving credit line to $10 million, and a new $10 million five-year
term loan, of which approximately $3.2 million was used to retire the
outstanding balance on our previous term loan. We believe that these credit
facilities will be sufficient to fund our current operational, capital
investment and acquisition plans.

     Through September 30, 2005, we marketed pharmaceutical products directly to
patients throughout our network and we had contracted with ivpcare, inc. to
provide certain business services related to the distribution of and accounting
for these sales. Effective October 1, 2005, this agreement was terminated and
replaced by a new agreement between us and ivpcare, inc. Under the terms of the
new agreement, we are no longer a direct distributor of pharmaceutical products
to patients, as this function is being performed directly by ivpcare. Our
responsibilities are limited to marketing the products for which we will be
compensated. This compensation will approximate our previous contribution from
those pharmaceutical sales and services, and will be shown on a "net" rather
than "gross" basis. As a result, as of October 1, 2005, we no longer record
pharmaceutical sales, the related cost of sales and other costs related to
pharmaceutical distribution. We anticipate significant decreases in revenues and
cost of sales; however (assuming the same volume of pharmaceutical products is
distributed) contribution from operations and income before income taxes, as
well as net income, will be virtually unaffected by this contract change.

     On May 23, 2005, the Company declared a 30% stock split effected in the
form of a stock dividend for all holders of record as of June 8, 2005. As a
result of this dividend, 1,129,141 new shares of the Company's common stock were
issued on the payment date of June 22, 2005. No fractional shares were issued as
all fractional amounts were rounded up to the next whole share. All weighted
average shares outstanding and earnings per share calculations have been
restated to reflect the stock split.

     Effective January 1, 2005, we signed a FertilityPartners agreement to
supply a complete range of business, marketing and facility services to the
Reproductive Partners Medical Group, Inc. or RPMG, a fertility practice
comprised of six physicians in the Southern California market. Under the terms
of this 25-year agreement, our service fees are comprised of reimbursed costs of

                                       12
<PAGE>


services, a tiered percentage of revenues, and an additional fixed percentage of
RPMG's earnings. We also committed up to $0.5 million to fund any necessary
capital needs of the practice.


     Effective January 1, 2005, the Company became a minority equity investor in
the Assisted Reproductive Technology Insurance Company, LTD, ("ARTIC"). ARTIC is
incorporated as an off-shore captive insurance company designed to offer
malpractice insurance to physicians and related facilities within the IntegraMed
network. IntegraMed's equity investment of $50,000 represents a 10% ownership
stake, which is accounted for on the equity basis. The remaining equity of ARTIC
is owned by participating physician groups. IntegraMed has agreed to provide
certain administrative and risk management related services to ARTIC for a
predetermined fee.


Results of Operations

     The following table shows the percentage of net revenue represented by
various expenses and other income items reflected in our statement of operations
for the quarters ended March 31, 2006 and 2005:

                                                              For the
                                                         three-month period
                                                            ended March 31,
                                                         -------------------
                                                          2006         2005
                                                         ------      -------
         Revenues, net:
           Provider services...........................   91.3%       80.5%
           Consumer services...........................    8.7%       19.5%
                                                         -----       -----
             Total revenues............................  100.0%      100.0%

         Costs of services incurred:
           Provider services...........................   82.2%       72.0%
           Consumer services...........................    5.4%       17.5%
                                                          -----       -----
             Total costs of service....................   87.6%       89.5%

         Contribution:
           Provider services...........................    9.1%        8.5%
           Consumer services...........................    3.3%        2.0%
                                                          -----       -----
             Total contribution........................   12.4%       10.5%


         General and administrative expenses...........   10.0%        8.9%
         Interest income...............................   (0.7)%      (0.3)%
         Interest expense..............................    0.5%        0.3%
                                                          -----       -----
                Total other expenses...................    9.8%        8.9%

         Income from operations before income taxes....    2.6%        1.6%
         Income tax provision..........................    1.0%        0.6%
                                                         -----       -----
         Net income ...................................    1.6%        1.0%


Three Months Ended March 31, 2006 Compared to Three Months Ended March 31, 2005

       Our revenues decreased by $1.5 million, or 4.8%, to $30.4 million for the
three months ended March 31, 2006, as compared to $32.0 million for the same
period in 2005. The first quarter of 2005 included pharmaceutical distribution
revenue of $4.7 million, which due to a contract amendment as discussed above,
reduced our pharmaceutical revenue but did not reduce our contribution from
pharmaceutical sales. Other significant factors affecting our reported revenues
were as follows:

                                       13
<PAGE>

(i) Provider Services -

              Revenues from our Provider Services unit, comprised primarily of
              our FertilityPartners centers, Affiliate members and ARTIC
              services, increased by $2.0 million, or 8.0% from the same quarter
              in the prior year. Approximately $1.6 million of this increase was
              the result of internal growth within our eight FertilityPartner
              locations and is largely attributable to consumer marketing
              campaigns initiated in the fourth quarter of 2005.

              Revenues from our Affiliate clinics increased approximately $0.4
              million in the first quarter of 2006 relative to the first quarter
              of 2005, reflecting both our growing network of affiliated
              fertility clinics, which increased from seventeen clinics as of
              March 31, 2005 to nineteen clinics as of March 31, 2006, and our
              ability to increase sales penetration at these clinics.

(ii) Consumer Services -

              Our Shared Risk Refund program continued to see significant
              double-digit year-to-year growth with first quarter 2006 revenues
              of $2.5 million, an increase of $1.0 million, or 66%, above 2005
              revenues of $1.5 million for the same period. We believe that this
              program will show continued growth and are working to increase the
              acceptance and sales penetration of this product to targeted
              FertilityPartner and Affiliates locations within our network.

              Pharmaceutical revenue was $0.2 million for quarter ended March
              31, 2006, compared to $4.7 million for the same quarter in 2005.
              This reduction in revenue is primarily the result of a change in
              contract terms we initiated with our strategic partner in the
              pharmaceutical business, which became effective on October 1,
              2005. Under the new contract terms, we no longer record the sales
              of pharmaceutical products as revenue and the cost of these
              products as costs of sales, but rather report net marketing fees
              associated with those sales. While these new terms do have an
              effect on our reported revenues, they will not have any impact on
              our net profit from those sales. As a result, reported revenues
              for 2006 are not directly comparable with 2005 results.


     Contribution for the quarter ended March 31, 2006 of $3.8 million increased
approximately $0.4 million, or 12.9%, from the same quarter in 2005. As a
percentage of revenue, our contribution margin for the quarter increased to
12.4% in 2006 relative to 10.5% in 2005 due primarily to the current
presentation of "net pharmaceutical revenue" as discussed above. The following
factors had a significant impact on contribution:

(i) Provider Services -

               Contribution from our FertilityPartners segment of $2.5 million
              for the first quarter of 2006 was essentially even with the
              contribution in the prior year. Despite revenue growth of 8%,
              previously disclosed fee reductions at three FertilityPartners
              clinics reduced contribution growth. The year 2006 represents the
              final year of our multi-year fee realignment program. With the fee
              structures we currently have in place, we expect that continued
              revenue growth in future years will directly translate into growth
              in contribution.

              Our Affiliate clinics generated contribution of $0.3 million in
              2006, an increase of $0.1 million from their contribution in 2005.
              This increase is primarily the result of a net addition of two
              Affiliate clinics to our network since the first quarter of 2005.

(ii) Consumer Services -

              Contribution from our Shared Risk Refund program rose by $0.4
              million, or 92%, to $0.9 million for the quarter ended March 31,
              2006, from $0.5 million in 2005. This growth is attributable to
              increased patient volume and continued favorable pregnancy
              outcomes, especially during early treatment cycles.

                                       14
<PAGE>

              Pharmaceutical contribution of $0.2 million in 2006 was consistent
              with the contribution level in 2005. As previously stated, the
              change in contract terms with our strategic partner in the
              pharmaceutical business was designed to have no effect on our
              contribution from those underlying sales.


     General and Administrative expenses are comprised of salaries, benefits,
corporate regulatory, operational, administrative and support costs which are
not specifically related to our clinical patient care or other product
offerings. These costs were $3.1 million in 2006, compared to $2.8 million for
the same period in 2005. Approximately $0.1 million of this increase relates to
wage and benefit items, with the remaining $0.2 million representing an increase
in general support and administrative costs.

     Interest income increased to $221,000 for the quarter ended March 31, 2006,
from $100,000 in 2004. This increase is primarily attributed to interest income
earned on capital investments at several FertilityPartners clinics. Interest
expense increased to $159,000 for the first quarter of 2006, from $97,000 in
2005, primarily as a result of interest charges on our existing bank debt, which
is $4.2 million higher than the balance outstanding in 2005.

     Our provision for income tax was approximately $0.3 million in 2006, or
38.3% of pre-tax income, compared to $0.2 million, or 37.5% of pre-tax income in
2005, with the increase of $0.1 million resulting primarily from higher income
levels in 2006 versus 2005. Our effective tax rates for both 2006 and 2005
reflect provisions for both state and federal income taxes.


Off-balance Sheet Arrangements

   FASB Interpretation No. 46 (FIN 46R) "Consolidation of Variable Interest
Entities" ("VIE's") addresses how a business enterprise should evaluate whether
it has a controlling financial interest in an entity through means other than
voting rights and accordingly should consolidate the entity. As part of our
ongoing business, we do not participate in transactions that generate
relationships with unconsolidated entities or financial partnerships, such as
entities often referred to as structured finance or VIE's, which would have been
established for the purpose of facilitating off-balance sheet arrangements or
other contractually narrow or limited purposes. As of March 31, 2006, we do not
have an interest in any VIE's where we are the primary beneficiary, therefore
the adoption of FIN 46 had no impact on our financial statements.

 Liquidity and Capital Resources

     As of March 31, 2006, we had approximately $19.9 million in cash and cash
equivalents on hand as compared to $22.5 million at December 31, 2005.
Additionally, we had working capital of approximately $7.9 million, at March 31,
2006, an increase of $1.2 million from working capital of $6.7 million as of
December 31, 2005. Our increased working capital is partially attributed to a
reduction in accrued liabilities and reduced balances due to medical practices.

     Shared Risk Refund patient deposits, which are reflected as a current
liability, represent funds received from patients in advance of treatment
cycles. These deposits, which represent prepayments of future revenues from
patients without full insurance coverage, totaled approximately $5.0 million and
$4.7 million as of March 31, 2006 and December 31, 2005, respectively. These
deposits are a significant source of recurring cash flow and represent
interest-free financing for us.

     As of March 31, 2006, we did not have any significant contractual
commitments for the acquisition of fixed assets or construction of leasehold
improvements. However, we anticipate upcoming capital expenditures of
approximately $3.1 million for the remainder of 2006. These expenditures are
primarily related to the expansion of our existing FertilityPartners centers. We
believe that working capital, specifically cash and cash equivalents, remain at
adequate levels to fund our operations and our commitments for fixed asset
acquisitions. We also believe that the cash flows from our operations plus our
available credit facility will be sufficient to provide for our future liquidity
needs for the next twelve months.

                                       15
<PAGE>

     In December 2005, we amended our existing credit facility with Bank of
America. The amended facility is comprised of a $10.0 million three-year
revolving line of credit and a $10.0 million 5-year term loan. As of March 31,
2006, approximately $9.6 million of the term loan was outstanding with a
remaining term of 4.75 years, and no balance was outstanding under the revolving
line of credit.

     Each component of this amended credit facility bears interest by reference
to Bank of America's prime rate or LIBOR, at our option, plus a margin, which is
dependent upon a leverage test, ranging from 1.75% to 2.50% in the case of
LIBOR-based loans. Prime-based loans are made at Bank of America's prime rate
and do not contain an additional margin. Interest on the prime-based loans is
payable monthly and interest on LIBOR-based loans is payable on the last day of
each applicable interest period. As of March 31, 2006, interest on both the term
loan and revolving credit line were payable at a rate of approximately 6.36%.
Unused amounts under the working capital revolver bear a commitment fee of 0.25%
and are payable quarterly. Availability of borrowings under the working capital
revolver is based on eligible accounts receivable, as defined in the credit
agreement. As of March 31, 2006, under the revolving line of credit the full
amount of $10.0 million was available, of which none was outstanding. The Bank
of America credit facility is collateralized by all of our assets. As of March
31, 2006, we were in full compliance with all applicable debt covenants.

     We are also continuously reviewing our credit agreements and may renew,
revise or enter into new agreements from time to time as deemed necessary.

Significant Contractual Obligations and Other Commercial Commitments:

     The following summarizes our contractual obligations and other commercial
commitments at March 31, 2006, and the effect such obligations are expected to
have on our liquidity and cash flows in future periods.
<TABLE>
<CAPTION>

                                                               Payments Due by Period

                                      Total     Less than 1 year     1 - 3 years     4 - 5 years    After 5 years
                                 -------------- ----------------  ----------------   -----------    -------------

<S>                              <C>                <C>             <C>              <C>             <C>
Notes Payable.................    $ 9,643,000       $1,428,000       $ 2,858,000     $ 5,357,000    $        --
Capital lease obligations.....        129,000           72,000            57,000              --             --
Operating leases..............     47,204,000        6,509,000        10,901,000       8,944,000     20,850,000
FertilityPartners capital and
    other obligations.........        500,000          500,000                --               --            --
Total contractual cash
    obligations...............    $57,476,000       $8,509,000       $13,816,000     $14,301,000    $20,850,000

                                                      Amount of Commitment Expiration Per Period

                                   Total        Less than 1 year    1 - 3 years     4 - 5 years    After 5 years
                                 --------       ----------------  ----------------  -------------  -------------
Lines of credit...............    $10,000,000       $       --       $10,000,000     $        --$             --
</TABLE>

           We also have commitments to provide working capital financing to our
FertilityPartners locations. A significant portion of this commitment relates to
our transactions with the medical practices themselves. Our responsibilities to
the medical practices are to provide financing for their accounts receivable and
to hold patient deposits on their behalf as well as undistributed physician
earnings. Disbursements to the medical practices generally occur on or before
the 20th business day of each month. The medical practice's repayment hierarchy
consists of the following:

(i) We provide a cash credit to the practice for billings to patients and
insurance companies;

(ii) We reduce the cash credit for clinic expenses that we have incurred on
behalf of the practice;

(iii) We reduce the cash credit for the base portion of our Service Fee which
relates to the FertilityPartners revenues;

                                       16
<PAGE>

(iv) We reduce the cash credit for the variable portion of our Service Fee which
relates to the FertilityPartners earnings; and

(v) We disburse to the medical practice the remaining cash amount which
represents the physicians undistributed earnings.

     We are also responsible for the collection of the FertilityPartners
accounts receivables, which we finance with full recourse. We continuously fund
these needs from our cash flow from operations, the collection of prior months'
receivables and deposits from patients in advance of treatment. If delays in
repayment are incurred, which have not as yet been encountered, we could draw on
our existing working capital line of credit. We also make payments on behalf of
the FertilityPartners for which we are reimbursed in the short-term. Other than
these payments, as a general course, we do not make other advances to the
medical practice. We have no other funding commitments to the FertilityPartners.

New Accounting Pronouncements

     At this time, there are no recently issued accounting standards which are
expected to have a material impact on us.


Forward Looking Statements

     This Form 10-Q and discussions and/or announcements made by or on behalf of
us, contain certain forward-looking statements regarding events and/or
anticipated results within the meaning of the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995, the attainment of which
involves various risks and uncertainties. Forward-looking statements may be
identified by the use of forward-looking terminology such as, "may", "will",
"expect", "believe", "estimate", "anticipate", "continue", or similar terms,
variations of those terms or the negative of those terms. Our actual results may
differ materially from those described in these forward-looking statements due
to the following factors: our ability to acquire additional FertilityPartners
agreements, our ability to raise additional debt and/or equity capital to
finance future growth, the loss of significant FertilityPartners agreement(s),
the profitability or lack thereof at fertility centers serviced by us, increases
in overhead due to expansion, the exclusion of fertility and ART services from
insurance coverage, government laws and regulation regarding health care,
changes in managed care contracting, the timely development of and acceptance of
new fertility, and ART and/or genetic technologies and techniques. We are under
no obligation to (and expressly disclaim any such obligation) update or alter
any forward-looking statements whether as a result of new information, future
events or otherwise.


                                       17
<PAGE>

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

     Our interest income and expense items are sensitive to changes in the
general level of interest rates. At March 31, 2006 we had an outstanding balance
of approximately $9.7 million on our term loan. This borrowing has a remaining
term of 4.75 years, and bears interest at either the Prime Rate, or at LIBOR
plus a margin. As of March 31, 2006, this borrowing had an interest rate of
approximately 6.36%. We also receive interest income from short-term investments
and certain advances to FertilityPartner clinics, both of which are tied to the
Prime Rate. As of March 31, 2006, a one percent change in interest rates would
impact our pre-tax and net income by less than $10,000. As of March 31, 2006, we
have not entered into any interest rate swap transactions.


Item 4. Controls and Procedures


     (a) Evaluation of disclosure controls and procedures.


     Under the supervision and with the participation of our management,
including our Chief Executive Officer and Chief Financial Officer, we evaluated
the effectiveness of the design and operation of our disclosure controls and
procedures (as defined in Rule 13a-15 under the Exchange Act) as of March 31,
2006 (the "Evaluation Date"). Based upon that evaluation, the Chief Executive
Officer and Chief Financial Officer concluded that, as of the Evaluation Date,
our disclosure controls and procedures were effective in timely alerting them to
the material information relating to us required to be included in our periodic
SEC filings.


     Section 404 of the Sarbanes-Oxley Act requires us to provide an assessment
of the effectiveness of our internal control over financial reporting as of the
end of fiscal year 2007. We are in the process of performing the system and
process documentation, evaluation and testing necessary to make its assessment.
We have not completed this process or its assessment. In the process of
evaluation and testing, we may identify deficiencies that will require
remediation.


     (b) Changes in internal controls.

     As of the end of the period covered by our restated Form 10-K, we
identified and disclosed two material weaknesses in our internal control over
financial reporting. A weakness at a FertilityPartner location was comprised of
a lack of sufficient oversight over, and the proper segregation of, duties with
respect to the processes of initiating, authorizing, recording and processing
certain period end closing transactions, as well as the design effectiveness of
related fraud detection controls. To remediate this material weakness, we have
made certain personnel changes, changes in assigned roles and responsibilities,
and changes in procedures and processes for certain transactions. The other
weakness relates to not properly accounting for the deferred income tax aspects
of acquiring the stock of Reproductive Partners, Inc., in January 2005. To
remediate this weakness we have taken steps to supplement our existing staff
with external expertise in tax accounting and disclosure.

     Other than these changes, there were no significant changes made in our
internal controls during the period covered by this report or, to our knowledge,
in other factors that could significantly affect these controls subsequent to
the date of their evaluation.


                                       18
<PAGE>

Part II -         OTHER INFORMATION

     Item 1.      Legal Proceedings.

                     From time to time, we are party to legal proceedings in the
                     ordinary course of business. As of March 31, 2006, none of
                     these proceedings is expected to have a material adverse
                     effect on our financial position, results of operations or
                     cash flow.

     Item 2.      Unregistered Sales of Equity Securities and Use of Proceeds.

                     None


     Item 3.      Defaults Upon Senior Securities.
                     None.

     Item 4.      Submission of Matters to Vote of Security Holders.
                     None.

     Item 5.      Other Information.
                     None.

     Item 6.      Exhibits.

                  See Index to Exhibits on Page 21.





                                       19
<PAGE>




                                   SIGNATURES



         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                  INTEGRAMED AMERICA, INC.
                                  (Registrant)




Date:    December 27, 2006        By:  /s/:John W. Hlywak, Jr.
                                           ----------------------------
                                           John W. Hlywak, Jr.
                                           Executive Vice President and
                                           Chief Financial Officer
                                           (Principal Financial and
                                           Accounting Officer)



                                       20
<PAGE>


                                INDEX TO EXHIBITS

Exhibit
Number                               Exhibit
------                               -------

3.2(d)  --  Copy of By-laws of Registrant (as Amended on March 6, 2006) filed as
            exhibit with identical exhibit number to Registrant's Report on Form
            10-Q for the period ended March 31, 2006.

31.1    --  CEO Certification Pursuant to 18 U.S.C. ss. 1350 as Adopted Pursuant
            to Section 302 of the  Sarbanes-Oxley Act of 2002 dated December 27,
            2006.

31.2    --  CFO Certification Pursuant to 18 U.S.C. ss. 1350 as Adopted Pursuant
            to Section 302 of the  Sarbanes-Oxley Act of 2002 dated December 27,
            2006.


32.1    --  CEO Certification Pursuant to 18 U.S.C. ss. 1350 as Adopted Pursuant
            to Section 906 of the  Sarbanes-Oxley Act of 2002 dated December 27,
            2006.

32.2    --  CFO Certification Pursuant to 18 U.S.C. ss. 1350 as Adopted Pursuant
            to Section 906 of the  Sarbanes-Oxley Act of 2002 dated December 27,
            2006.




                                       21